Press Releases

Open Letter from UsAgainstAlzheimer’s Co-Founder and Chairman Specifies Initial Next Steps to Achieve Critical Advancements Toward Effective Treatments and a Cure

WASHINGTON, DC—In a letter released today by UsAgainstAlzheimer’s, Co-Founder and Chairman George Vradenburg said the negative clinical trial of a once-promising Alzheimer’s drug, Solanezumab, which showed clinically insignificant ability to slow cognitive decline in Alzheimer’s patients, should be viewed not as a failure, but as a development that “provides valuable lessons and suggests a way forward in the fight against Alzheimer’s.”

WASHINGTON, DC—Following the passing of the 21st Century Cures Act by the U.S. Senate on Wednesday, UsAgainstAlzheimer’s applauds the bipartisan action by Congress to hasten and strengthen the nation’s abilities to develop, test and deliver game-changing therapies for diseases and illnesses that cripple families.

WASHINGTON, DC—Following today’s announcement that Eli Lilly’s drug that would slow memory loss in people with mild cases of Alzheimer’s disease failed Phase III clinical trials, UsAgainstAlzheimer’s emphasizes that while this news is a setback for the millions of people around the world with dementia, the pipeline could see more successful results in the near future.

WASHINGTON, DC, November 15, 2016 – A multigenerational movement to defeat Alzheimer’s disease, buoyed by the partnership of UsAgainstAlzheimer’s  and a host of national, state and local Alzheimer’s-serving organizations, was catalyzed during this fall’s National Alzheimer’s Summit in Washington, DC, proving to be a decisive moment in a fight against a disease that is the nation’s third-leading cause of death.  

UsAgainstAlzheimer’s Urges Executive and Congressional Action in the First 100 Days and Beyond

WASHINGTON, DC, November 10, 2016—As the United States turns its attention to forging constructive transitions in the executive and legislative branches, UsAgainstAlzheimer’s (UsA2) calls upon the newly elected Administration and Congress to shepherd in an era that finally addresses the serious national priority that is Alzheimer’s and related dementias, and takes immediate action to increase Alzheimer’s research funding and to support patients and caregivers.


^ Back to Top